Presence and distribution of the citrulline peak in patients with MS according to the VOI site revealed by 1H-MR Spectroscopy
Patient No. | Citrulline Peak on 1H-MR Spectroscopy | ||
---|---|---|---|
NAWM | CDL | EDL | |
1 | + | – | na |
2 | na | – | – |
3 | na | – | na |
4 | + | – | – |
5 | – | na | na |
6 | + | + | na |
7 | + | + | na |
8 | – | – | na |
9 | + | – | na |
10 | – | – | + |
11 | – | – | na |
12 | – | + | – |
13 | + | – | na |
14 | – | – | – |
15 | – | – | – |
16 | – | – | na |
17 | – | na | na |
18 | + | + | – |
19 | – | – | na |
20 | – | – | na |
21 | + | + | – |
22 | – | + | na |
23 | – | – | na |
24 | – | + | na |
25 | – | – | na |
26 | – | – | na |
27 | – | – | na |
Note:—na indicates that MR spectroscopy could not be performed due to absence of such a VOI site; +, present; –, absent; MS, multiple sclerosis; VOI, voxel of interest; NAWM, normal-appearing white matter; CDL, chronic demyelinating lesions; EDL, enhanced demyelinating lesions.